Study Summary
This trial is testing a new drug, INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5). This is the first time this drug is being tested in humans. The trial has three parts.
- Chondrosarcoma
- Sarcoma
- Solid Tumors
- Mesothelioma
- Stomach Cancer
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Ewing Sarcoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 5 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Trial Design
11 Treatment Groups
Combination Expansion Colorectal Adenocarcinoma
1 of 11
Dose Escalation
1 of 11
Expansion Malignant Pleural Mesothelioma
1 of 11
Expansion Gastric Adenocarcinoma
1 of 11
Expansion Colorectal Adenocarcinoma
1 of 11
Expansion Sarcomas
1 of 11
Combination Expansion Malignant Pleural Mesothelioma
1 of 11
Combination Expansion Pancreatic Adenocarcinoma
1 of 11
Combination Expansion Ewing Sarcoma
1 of 11
Expansion Solid Tumors
1 of 11
Combination Expansion SDH-deficient solid tumors or GIST
1 of 11
Experimental Treatment
240 Total Participants · 11 Treatment Groups
Primary Treatment: INBRX-109 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the extent of the geographic scope for this clinical trial?
"This study is being run in multiple locations, with Heather Keaney leading the charge at New York's centre, Memorial Sloan Kettering Cancer Center located in Scottsdale and HonorHealth Research Institute based out of Chicago. A further 14 sites are also taking part." - Anonymous Online Contributor
What applications does INBRX-109 have in medical treatments?
"INBRX-109 is frequently used to treat initial stages of cancer. Additionally, it can be employed as a therapeutic agent for patients suffering from small cell lung cancer (sclc), advanced testicular cancers, and progression disease." - Anonymous Online Contributor
Has INBRX-109 been explored in any other clinical experiments?
"INBRX-109 was initially investigated in 1997 by City of Hope Comprehensive Cancer Center. Currently, there are 2742 concluded studies and 1681 active trials happening at multiple sites around New York City." - Anonymous Online Contributor
Has INBRX-109 attained regulatory authorization from the U.S. Food and Drug Administration?
"Our team at Power have assigned the safety of INBRX-109 a score of 1, in accordance with its status as an initial Phase 1 trial. This indicates that there is only limited information around both efficacy and safety." - Anonymous Online Contributor
Approximately how many participants have been recruited for this trial?
"Inhibrx, Inc., the sponsor of this study, requires a total of 240 participants that conform to the inclusion criteria. The research will be conducted at Heather Keaney in New York and Memorial Sloan Kettering Cancer Center in Arizona." - Anonymous Online Contributor
Are there any opportunities for individuals to sign up and participate in this research?
"Correct. Clinicaltrials.gov reveals that this research project, first posted on October 10th 2018, is actively seeking participants for recruitment. A total of 240 patients are required from 16 separate medical centres." - Anonymous Online Contributor
What objectives is this research venture hoping to realize?
"This two-year clinical trial is designed to assess the intensity and frequency of any adverse reactions associated with INBRX-109. In addition, immunogenicity, peak serum concentration (Cmax) and trough observed serum concentration (Ctrough) for this medication will be measured as secondary outcomes." - Anonymous Online Contributor